Abstract: The present disclosure refers to a composition with N-acetylcysteine and/or lysozyme; or N-acetylcysteine and microencapsulated gastroprotected lysozyme with pro biotic bacteria for use in the pharmacological treatment of gastric hyperacidity. Said composition is capable of restoring the stomach's own barrier effect, which is lost during the pharmacological treatment of gastric hyperacidity, and of minimizing the secondary effects due to said pharmacological treatment.

Abstract: Inoculation of ATM-deficient mice with probiotic microorganisms, such as L. johnsonii, changed immune parameters, decreased a marker of DNA damage and increased the lifespan of the mice. Compositions and methods described herein are useful for the treatment and prevention of Ataxia telangiectasia and other cancer-prone diseases, such as p53 deficiency-associated cancers. Compositions and methods of the present invention are also useful for treating and preventing radiation-induced toxicity to normal tissue in a subject being exposed to radiation. Compositions and methods of the invention can increase lifespan in a simple, non-invasive manner.

Abstract: The present invention relates to a Myoviridae bacteriophage Clo-PEP-1 that is isolated from the nature and can kill Clostridium perfringens cells specifically, which has the genome represented by nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12664BP), and a method for preventing and treating the infections of Clostridium perfringens cells using the composition comprising said bacteriophage as an active ingredient.

Abstract: The present invention relates to formulations made up from extracts from Ganoderma lucidum, rhizome of Coptis chinensis, Radix astragali, Nelumbo nucifera Gaertn, Chaenomeles speciosa, and Fructus Aurantii. Pursuant to the invention, the formulations are used to treat obesity and the biological sequelae of obesity including cholesterol levels and glucose levels. While not limited to any particular mechanism of action the formulations may assert their effects by altering gene expression, in particular, the expression of PPAR?, FABP4, CPT1, UCP2, and AMPK.

Abstract: The present invention relates to an improved multistep method for the production of an extract of Ginkgo biloba leaves for use as a drug.

Abstract: The present invention is directed to compositions and methods comprising a cannabis-infused milk. The milk can be used as an oral dosage form for pharmaceutical delivery of cannabinoids.

Abstract: Synthesis of Nuxia oppositifolia nanoparticles includes providing an extract of Nuxia oppositifolia, dissolving the extract in alcohol to provide a mixture, adding water to the mixture to provide an aqueous solution, adding an acidic solution to the aqueous solution to form a final solution including Nuxia oppositifolia nanoparticles; and centrifuging the final solution to isolate the Nuxia oppositifolia nanoparticles.

Abstract: The invention relates to a (i) Vitamin A, a reaction product, a metabolite or a precursor of it and (ii) a plant extract of chamomile or an active component thereof, preferably for use in the treatment of cancer. The inventive composition may be provided as a medicament or a pharmaceutical composition. The at least one Chamomilla plant typically contained in the inventive compositions preferably comprises Matricaria recutita, more preferably fibers tubiformis of Matricaria recutita. Esters of Retinol typically contained in the inventive compositions typically comprise e.g. Retinyl acetate and a plant extract from the plant Matricaria recutita.

Abstract: The present invention provides compositions having synergistic antioxidant properties in the modulation of Toll-like receptor signaling for the promotion of homeostasis, immunity, energy conservation, protection of neural cells and anti-inflammatory responses, said compositions comprising plant and/or fruit extracts and a natural sweetener with high oxidation potential as defined by ORAC value.

Abstract: The present invention relates to a composition, and methods of using the composition, for minimizing the harmful effects associated with alcohol consumption. The composition includes a plurality of ingredients, which when combined, have the unexpected effect of increasing one or more metabolic pathways in the individual. As the metabolic rate is increased, alcohol is burned off, or utilized as energy source, and occurs at a considerably much faster rate than under normal physiological means. It is believed that the composition may have an effect on the brain causing it to increase metabolic rates. By administering the composition to an inebriated individual, the rate at which a person sobers up, occurs at a faster rate than would occur under normal physiological time frames.

Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.

Abstract: The present invention relates, in general, to a method of treating patients undergoing enzyme replacement therapy (ERT) or other therapy involving the administration of a proteinaceous therapeutic agent as well gene replacement therapy with non-viral or viral vectors, or other therapeutic modality or modalities, used alone or in combination, which involve the administration of exogenous substances for potential therapeutic benefit, including, but not limited to DNA vaccines, siRNA, splice-site switching oligomers (SSOs) as well as RNA-based nanoparticles (RNPs) and nanovaccines. The invention further relates to compounds and compositions suitable for use in such methods.

Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide, peptides, or both. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The present invention relates, inter alia, to a method comprising administering to a subject having high output shock and undergoing treatment with a catecholamine at a dose equivalent to at least about 0.2 mcg/kg/min of norepinephrine a dose of angiotensin II which is effective to raise the blood pressure of the subject to a mean arterial pressure (MAP) of about 65 mm or above, and which is effective to reduce the dose of the catecholamine required to maintain a MAP of about 65 mm to the equivalent of about 0.05-0.2 mcg/kg/min norepinephrine or less, or to the equivalent of about 0.05 mcg/kg/min norepinephrine or less.

Abstract: A method for synchronizing ovulation in sows and gilts by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogs, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred, without heat detection, at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

Abstract: Described herein are systems and methods for attracting and trapping cancer cells at a specific site where focal radiation and/or surgical resection and/or chemotherapeutics can eliminate them.

Abstract: The present invention relates to a method for treating or preventing either one or both of an inflammatory disease and an autoimmune disease in a patient, wherein the method comprises providing a pharmaceutical composition containing a therapeutically effective amount of soluble Fc?R; administering said composition to a patient, followed by a safety period of several weeks, followed by a subsequent treatment cycle of at least two weekly administrations, wherein said therapeutically effective amount is effective to treat or prevent said disease in said patient. The present invention also provides a pharmaceutical composition in the form of a multiple-dosage-kit which contains sufficient amounts of administration doses of soluble Fc?R for effectively treating or preventing inflammatory diseases and/or autoimmune diseases in a patient.

Abstract: The present invention is directed to a peptide conjugate comprising an alpha-amino protecting moiety, a peptide comprising the amino acid sequence at least 3 amino-acid long derived from the C?-terminus of PAR-1, or an active variant thereof and a protease-disabling moiety. The present invention is further directed to pharmaceutical compositions comprising the peptide conjugate and use thereof for treating diseases and disorder associated with excessive PAR-1 activity.

Abstract: Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of Il-12 for bone marrow preservation or recovery.

Abstract: PEGylated diaspirin-crosslinked hemoglobin conjugates having high oxygen affinity are described which have enhanced nitrite reductase activity to deliver oxygen, carbon monoxide, nitric oxide or mixtures thereof to tissues to treat various diseases and conditions.

Abstract: Methods for reducing the environmental impact of animal waste are described. In particular embodiments, the methods comprise administering to an animal an enzyme, such as alkaline phosphatase, that is effective to reduce the amount of a detrimental compound, such as ammonia or phosphorous, that is present in or released from animal waste. Also provided is a method for increasing phosphorus digestion in an animal. Compositions suitable for use in such methods are also described.

Abstract: This document provides methods and materials for treating cancer. For example, methods and materials for identifying antigens and combinations of antigens that can be used to treat cancer as well as combinations of antigens having the ability to reduce established tumors within a mammal (e.g., a human) are provided.

Abstract: Agents, compositions, methods and kits useful for the treatment and diagnosis of Staphylococcal intramammary infection are disclosed. The agents, compositions, methods and kits are derived from genes expressed during Staphylococcal intramammary infection, and more particularly genes SACOL0029, SACOL0264, SACOL0442, SACOL0718, SACOL0720, SACOL1353, SACOL1416, SACOL1611, SACOL1944, SACOL2144, SACOL2365 or SACOL2599, based on the gene nomenclature from the Staphylococcus aureus COL (SACOL) genome.

Abstract: The present invention relates to an immunogenic composition comprising: a) a modified live H3 virus of swine influenza, and b) a modified live H1 virus of swine influenza. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by swine influenza virus in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

Abstract: The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.

Abstract: A method for preserving a polypeptide comprising: (a) providing an aqueous solution of (i) the polypeptide, (ii) one or more sugars, and (iii) a compound of formula (I) or a physiologically acceptable salt or ester thereof and/or a compound of formula (II) or a physiologically acceptable salt or ester thereof; and (b) drying the solution to form a composition incorporating the polypeptide.

Abstract: A system for the physical manipulation of free magnetic rotors in a circulatory system using a remotely placed magnetic field-generating stator is provided. In one embodiment, the invention relates to the control of magnetic particles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow. Examples of vascular occlusions targeted by the system include, but are not limited to, atherosclerotic plaques, including fibrous caps, fatty buildup, coronary occlusions, arterial stenosis, restenosis, vein thrombi, arterial thrombi, cerebral thrombi, embolisms, hemorrhages, other blood clots, and very small vessels.

Abstract: A process for treating glaucoma whereby the treatment can be accomplished by the use of medication or by surgery, or both, in order to control or prevent the occurrence of glaucoma. The optic nerve is aligned within and between two distinct pressurized spaces and within the dural sheath, the intraocular space and the intracranial space having an intraocular pressure (IOP) and an intracranial pressure (ICP), respectively. Medicine can be administered to raise the intracranial pressure in order to reach a desirable lower translaminar pressure difference across these two pressurized spaces which are separated by the lamina cribrosa in order to treat glaucoma. An alternate closely related mode of the treatment process is the implanting of a shunt substantially between the intraocular space and the intracranial space in order to beneficially equalize pressure differentials across the intraocular space and the intracranial space.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.

Abstract: A liquid composition comprising a GLP-1 agonist or/and a pharmacologically tolerable salt thereof, an insulin or/and a pharmacologically tolerable salt thereof, and, optionally, at least one pharmaceutically acceptable excipient, wherein the composition comprises methionine, as add-on therapy with metformin where appropriate.

Abstract: The present invention relates to compositions comprising therapeutic and/or diagnostic anionic agents together with cationic peptides and their use in methods for delivering the anionic agents to bladder cells.

Abstract: A substantially surface active agent-free and foam adjuvant-free composition which includes a hydrophobic solvent, a wax and a propellant. A substantially surface active agent-free and foam adjuvant-free composition, further comprising, a tetracycline antibiotic, or one or More other active agents. A method of treatment, using a substantially surface active agent-free and substantially foam adjuvant-free composition.

Abstract: The present disclosure relates to a dendrimer-based conjugate of the formula Vm-D-C-D?-(T-F)n, which is useful for tumor targeting drug delivery. The use of asymmetric dendrimers allow for specific targeting as well as synthetic reproducibility.

Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.

Abstract: Lipid conjugates for enhanced delivery of cargo to the lymph nodes are disclosed. The lipid conjugates typically include three domains: a lipophilic domain that binds to albumin, a polar block domain, and a cargo such as a molecular adjuvant or immunostimulatory compound (such as an oligonucleotide) or antigenic peptide. Depending on the cargo, the length and compositions of the polar block can be tailored to push the equilibrium toward albumin binding, stable micelle formation, or cell insertion. The conjugates can be administered to a subject, for example, a subject with cancer or an infection, to induce or enhance a robust immune response in the subject.

Abstract: Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

Abstract: A compound which is selected from A: A O OO O O O I O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N B: 5 B O OO O O O Br O NH O O O O O O O O N H N H N H OO OH H O N N OO H N N; and C C O O N H N H O N H OO OO O O N O OO O O O O NH O O O O O O O O N H N H N H OO OH H O N N OO OH H N N; and salts and solvates thereof.

Abstract: A therapeutic method for mitigating bone loss. This method includes preparing and administering to animals intraperitoneally or orally a therapeutic agent containing metallic gold cluster molecules as an active ingredient.

Abstract: Provided herein are fullerene compositions, and methods of preparing fullerene compositions. More particularly, the fullerene compositions include a fullerene-polymer complex having a fullerene and a non-conjugated hydrophilic or amphiphilic polymer. The non-conjugated polymer is substituted with a substituent having a functional group capable of forming intermolecular interactions with the fullerene via pi-stacking.

Abstract: As a substance used as a contrast agent for a method of nuclear magnetic resonance analysis or a method of magnetic resonance imaging, a substance with high selectivity and high sensitivity was demanded. According to the present invention, when a polymer having, in a side chain thereof, a sequence of a 1H—13C—15N, 1H—15N—13C or 1H—13C—13C bond, that is, a structure labeled with stable isotopes of 13C and 15N, is used, the abundance of such a sequence in one molecule can be increased, and hence, high selectivity and higher sensitivity can be attained when used as a contrast agent.

Abstract: Provided is a radioactive labeled compound capable of detecting a secondary mutation of an epidermal growth factor receptor, where the compound is represented by Formula (1) or a pharmaceutically acceptable salt thereof, where Y, L1, R1 and R2 are as defined.

Abstract: The present invention provides targeted nanoplex molecules which carry multimodality imaging reporters together with target enzyme inhibitors such as siRNAs and target prodrug enzymes, that are useful for theranostic imaging of cells and diseases, including, for example, various cancers, and including metastatic prostate cancer. The nanoplex molecules of the present invention provide a platform technology toward many cancer subtypes and alternative therapeutic targets. Downregulation of specific pathways using targeted enzyme inhibitors further provides unique opportunities to target cancer cells selectively while sparing normal tissue. The nanoplex molecule platform described herein has the ability to deliver multiple siRNA enzyme inhibitors. Methods of diagnosis and treatment of various diseases are also included.

Abstract: A system for treating, in particular cleansing, wounds with a fluid jet. The system includes a handpiece with a main body with a front end with an emergence opening for the emergence of the fluid jet. The system furthermore has at least one light-emitting light source, which irradiates aerosols created when cleansing the wound. The system enables wound cleansing with simultaneous decontamination of the aerosols created in the process such that the risk of contamination of the surroundings is reduced and preferably with simultaneously treating the wound with UV light.

Abstract: Disclosed is a system for reducing germs by means of plasma. To this end, a piezoelectric transformer is associated with a dielectric film. The peripheral edge of the dielectric film encloses an area to be sterilized, a cavity being formed thereby. A high-voltage end of the piezoelectric transformer is facing a side of the dielectric film facing away from the cavity. The plasma is ignited within the cavity.

Abstract: A system for disinfecting a fluid, including: a flow cell including one or more inlet ports and one or more outlet ports, wherein the flow cell is configured to communicate a fluid containing a biological contaminant from the one or more inlet ports to the one or more outlet portions through an interior portion thereof; and one or more point radiation sources disposed about the flow cell, wherein the one or more point radiation sources are operable for delivering radiation to the biological contaminant; wherein an interior surface of the flow cell is operable for reflecting the radiation delivered to the biological contaminant by the one or more point radiation sources; and wherein the interior surface of the flow cell is operable for reflecting the radiation delivered to the biological contaminant by the one or more point radiation sources such that a radiation intensity is uniform throughout the interior portion of the flow cell. In one exemplary embodiment, the flow cell is an integrating sphere.

Abstract: A water-absorbing resin composition including 100 parts by weight of water-absorbing resin particles and 0.01 to 1 part by weight of additive particles, wherein a percent by weight of the additive particles, (x [%]), based on 100% by weight of the water-absorbing resin particles in the composition, and weight ratio of free additive particles, (y), relative to the percent by weight, (x [%]), satisfy the following formula: 0.04(x)0.1?y?0.2(x)0.5.

Abstract: The invention relates to: —a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e.

Abstract: The present invention is directed to a novel method and apparatus for facilitating and improving efficient application of nanofibers to the surface of poorly conductive three-dimensional objects using electrospinning. The apparatus and associated methods of the present invention provide a much more direct connection between the object and the grounded plate collector while allowing the object to be supported above the collector in a manner which promotes nanofiber deposition over the top, bottom and side surfaces of the object, closely covering all of its surfaces with nanofibers. Moreover, the deposition of electrospun nanofibers according to various embodiments of the present invention expands electrospinning technology to greater numbers of applications in which three-dimensional coatings of a wide nature are advantageous.

Abstract: Described herein are molded dehydrated placental tissue compositions, and pharmaceutical compositions thereof. The compositions have numerous medical applications. Methods for making and using the molded dehydrated placental tissue compositions are also described herein.

Abstract: A bone void filler material is provided that is configured for sustained release of a therapeutic agent. The bone void filler material comprises a biodegradable matrix having ceramic particles and cement beads disposed within the matrix, the cement beads loaded with the therapeutic agent to cause sustained release of the therapeutic agent. Methods of use are also disclosed.